NCT07667673 Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH
| NCT ID | NCT07667673 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istanbul University - Cerrahpasa |
| Condition | Pulmonary Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-05-11 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-05-11 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1 pulmonary arterial hypertension (PAH). The study aims to determine whether incorporation of echocardiographic and cardiac magnetic resonance (CMR)-derived right ventricular parameters into established non-invasive risk assessment models results in risk reclassification and improves identification of patients at risk for short-term clinical worsening. Adult patients with established Group 1 PAH undergoing routine follow-up and with available right heart catheterization (RHC) and CMR data will be consecutively enrolled. Clinical, laboratory, echocardiographic, and follow-up data will be prospectively collected over a 6-month period. Associations between multimodality imaging findings, invasive hemodynamic measurements, risk classification, and short-term clinical outcomes will be evaluated.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of Group 1 pulmonary arterial hypertension (PAH) according to ESC/ERS guidelines * Followed at the study center with a diagnosis of PAH * Availability of right heart catheterization (RHC) and cardiac magnetic resonance (CMR) imaging data obtained within a clinically relevant time interval * Availability of analyzable clinical, imaging, and hemodynamic data * Willingness to participate in the study and provision of written informed consent Exclusion Criteria: * Age younger than 18 years * Pulmonary hypertension groups other than Group 1 PAH (Groups 2-5 PH) * Absence of either right heart catheterization or cardiac magnetic resonance imaging data within a clinically relevant time interval * Incomplete clinical or imaging data preventing analysis * Unavailable follow-up data
Contact & Investigator
Aybüke Geylan, MD
PRINCIPAL INVESTIGATOR
Istanbul University Cerrahpasa Institute of Cardiology
Frequently Asked Questions
Who can join the NCT07667673 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07667673 currently recruiting?
Yes, NCT07667673 is actively recruiting participants. Contact the research team at aybukegeylan@gmail.com for enrollment information.
Where is the NCT07667673 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07667673 clinical trial?
NCT07667673 is sponsored by Istanbul University - Cerrahpasa. The principal investigator is Aybüke Geylan, MD at Istanbul University Cerrahpasa Institute of Cardiology. The trial plans to enroll 50 participants.